{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-029193","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.360937+00:00","generated_at":"2026-06-11T11:02:51.666687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"VYNE Therapeutics Q2 net loss $10.1M; VYN201 phase 1b data due Q3 2023","bullets":["Net loss of $10.1M ($3.09 per share) vs $8.5M ($2.63) in Q2 2022; revenue flat at $0.1M.","Cash and restricted cash $20.7M as of June 30, 2023; expects to fund operations through end of 2023.","R&D expenses rose to $7.2M from $4.1M YoY, primarily due to VYN202 license payment and development costs.","VYN201 Phase 1b preliminary safety/efficacy data in nonsegmental vitiligo anticipated in Q3 2023.","VYN202 IND submission expected by year-end; Phase 1 trial to begin Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-029193","json":"https://secwatch.observer/filing/0001628280-23-029193.json","markdown":"https://secwatch.observer/filing/0001628280-23-029193.md","text":"https://secwatch.observer/filing/0001628280-23-029193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/0001628280-23-029193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/mnlo-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T11:02:51.666687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f958a7a75821717318a6eb6b33926bf92e94438","claim":"VYNE Therapeutics Inc. reported the three and six months ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09.","evidence_excerpt":"VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/0001628280-23-029193-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Net income","value":"Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}